BRAXIA SCIENTIFIC CORP - BRAXF STOCK NEWS

Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) is gaining media attention for its innovative ketamine treatments for depression. CEO Dr. Roger McIntyre is set to appear on CTV's W5 on October 23, 2021, discussing 'Psychedelic Healing'. The company was also featured in a Toronto Life article, highlighting ketamine's rapid effectiveness in treating mental disorders. Braxia operates clinics in major Canadian cities, aiming to alleviate the burden of brain-based mental illnesses.

Braxia Scientific Corp. announced the publication of a study in the Journal of the Royal Society of Medicine, led by CEO Dr. Roger McIntyre, focusing on suicide reduction in Canada during the COVID-19 pandemic. The study highlights a decrease in the suicide mortality rate from 10.82 to 7.34 per 100,000, attributing the decline to increased access to virtual psychiatric care. Braxia aims to further reduce suicidality through ketamine treatments and potential derivatives, emphasizing the importance of public policies prioritizing psychiatric services.

Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced encouraging preliminary findings from a clinical study suggesting that ketamine is effective as a standalone antidepressant for treatment-resistant depression (TRD). Conducted at the Canadian Rapid Treatment Centre of Excellence, the study involved 220 patients. Participants receiving intravenous (IV) ketamine monotherapy had response and remission rates of 39.1% and 17.4%, significantly outperforming those on adjunctive treatments. These results indicate ketamine's potential as a primary treatment option, impacting Braxia's drug discovery efforts.

Braxia Scientific Corp. reported a significant 80.3% revenue increase, reaching $407,075 for Q1 fiscal 2021. The company has exceeded its monthly IV Ketamine infusion targets, particularly at its new clinic in Montreal. Additionally, Braxia is advancing three funded clinical trials, including groundbreaking studies on ketamine and psilocybin for treating depression. Despite these gains, the company recorded a net loss of $1,091,568, influenced by share-based compensation expenses.

Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company, focused on innovative ketamine treatments for depression, also disclosed the issuance of 200,000 common shares valued at $62,000 to settle payments to an independent medical advisor. Braxia operates clinics across Canada and aims to transform mental health treatment. Forward-looking statements indicate potential risks related to regulatory approvals and treatment efficacy.

Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced its participation in the virtual Canaccord Genuity Annual Growth Conference, scheduled for August 10-12, 2021. CEO Dr. Roger McIntyre will present the company's initiatives focusing on novel therapeutics for depression and brain-based disorders. The presentation is set for August 10 at 11:30 a.m. ET. Braxia operates clinics providing ketamine treatments for mental health issues and is engaged in developing new drugs and delivery systems while striving to alleviate the burden of mental disorders.

Braxia Scientific Corp. reported its fiscal fourth-quarter and year-end results for the period ending March 31, 2021. The company generated revenues of $1,008,372 for the year, with a gross margin of $145,666. Major losses of $88,828,146 were primarily driven by a non-cash listing expense. Braxia expanded its clinic network to four locations in Canada and established direct billing with a health insurance provider for veterans. The company is advancing multiple clinical trials and initiatives in ketamine-assisted therapy while enhancing its management team.

Braxia Scientific Corp. has received $918,000 in funding from the Canadian Institutes of Health Research to investigate the efficacy of combining intravenous ketamine with internet-based cognitive behavioral therapy (iCBT) to reduce suicidality in individuals with depression. The clinical trial, ranked in the 94th percentile by CIHR, will be conducted in Mississauga and at other locations in Canada. Suicidality is a significant public health issue, being the second-leading cause of death among youth and young adults in Canada.

Braxia Scientific Corp. has established direct billing with Medavie Blue Cross for ketamine treatments, offering 100% coverage for qualifying Canadian military veterans. This initiative aims to alleviate the financial burden of treatments at the Canadian Rapid Treatment Centre of Excellence. It is estimated that around 16% of full-time Canadian Armed Forces personnel experience depression, highlighting the significance of this coverage.

CEO Dr. Roger McIntyre emphasized the importance of this development, noting a rise in clinic bookings and the positive impact of ketamine treatments on veterans suffering from mental health disorders.